P. Guimarães, Caio A M Tavares, Marcelo Franken, Pedro A. Lemos
2026.1.29European Heart Journal-Cardiovascular Pharmacotherapy
tlooto Summary
The population who may benefit more from P2Y12 inhibitor treatment after DAPT may benefit more from P2Y12 inhibitor therapy.
Abstract
Reducing the time exposure to dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has been an alternative approach to avoid bleeding in patients with acute coronary syndrome (ACS). 1,2 However, the population who may benefit more from P2Y12 inhibitor
Citation format
GUIMARÃES, P., et al. Aspirin may take a back row seat for non-st-segment elevation acute coronary syndrome after percutaneous coronary intervention. European Heart Journal-Cardiovascular Pharmacotherapy, 2026, 12(2): 60–61.